Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience;Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España

Medicina Clinica

Volumn 137, Issue 1, 2011, Pages 8-13

  López Rubio, Montserrat ^a   Morado, Marta ^b   Gaya, Ana ^c   Alonso Rosa, Dora ^d   Ojeda, Emilio ^e   Muñoz, Juan Antonio ^f   Pérez De Mendiguren, Begoña ^g   Monteagudo, María Dolores ^h   Durán, José María ⁱ   Fisac, Rosa María ^j   Moreno, Damián ^k   Villegas, Ana María ^l  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^h HOSPITAL DE MÓSTOLES   (Spain)

ⁱ Hospital del SAS   (Spain)

^j HOSPITAL GENERAL DE SEGOVIA   (Spain)

^k HOSPITAL INFANTA MARGARITA   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

Eculizumab; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

ECULIZUMAB;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FATIGUE; HEMOLYSIS; HUMAN; MENINGOCOCCOSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; SMOOTH MUSCLE; SPAIN; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MIDDLE AGED; SPAIN; YOUNG ADULT;

EID: 79958056645     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.09.035     Document Type: Article

References (29)

1. P. Hillmen, N.S. Young, J. Schubert, R.A. Brodsky, G. Socié, and P. Muus The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria N Engl J Med. 355 2006 1233 1243 (Pubitemid 44427447)
2. R.A. Brodsky, N.S. Young, E. Antonioli, A.M. Risitano, H. Schrezenmeier, and J. Schubert Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Blood. 111 2008 1840 1847 (Pubitemid 351451491)
3. P. Hillmen, S.M. Lewis, M. Bessler, L. Luzzatto, and J.V. Dacie Natural history of paroxysmal nocturnal hemoglobinuria N Engl J Med. 333 1995 1253 1258
4. R.P. De Latour, J.Y. Mary, C. Salanoubat, L. Terriou, G. Etienne, and M. Mohty Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories Blood. 112 2008 3099 3106
5. Kelly R, Richards S, Arnold L, Valters G, Cullen M, Hill A, et al. A spontaneous reduction of clone size in paroxysmal nocturnal hemoglobinuria patients treated with eculizumab for greater than 12 months. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 1992.
6. P. Hernández Campo, J. Almeida, and A. Orfao Hemoglobinuria paroxística nocturna Med Clin (Barc). 131 2008 617 630
7. M. Morado, D. Subirá, and M. López Rubio Hemoglobinuria paroxística nocturna: nuevos tratamientos y recomendaciones generales para su diagnóstico Med Clin (Barc). 134 2010 369 374
8. V.M. Moyo, G.L. Mukhina, E.S. Garrett, and R.A. Brodsky Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays Br J Haematol. 126 2004 133 138 (Pubitemid 38859494)
9. Muus P, Risitano AM, Castro-Malaspina HR, Jones M, Fuller S, Socie G. Clinical impact of unregulated terminal complement activity in never-transfused patients with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 4029.
10. G.L. Mukhina, J.T. Buckley, J.P. Barber, R.J. Jones, and R.A. Brodsky Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia Br J Haematol. 115 2001 476 482 (Pubitemid 34203519)
11. H. Wang, T. Chuhjo, H. Yamazaki, S. Shiobara, M. Teramura, and H. Mizoguchi Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis Eur J Haematol. 66 2001 200 205 (Pubitemid 32324587)
12. A. Tichelli, A. Gratwohl, A. Würsch, C. Nissen, and B. Speck Late haematological complications in severe aplastic anaemia Br J Haematol. 69 1998 413 418
13. M.M. De Planque, A. Bacigalupo, A. Würsch, J.M. Hows, A. Devergie, and N. Frickhofen Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT) Br J Haematol. 73 1989 121 126
14. G. Socie, M. Henry-Amar, A. Bacigalupo, J. Hows, A. Tichelli, and P. Ljungman Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party N Engl J Med. 329 1993 1152 1157
15. P. Hillmen, P. Muus, U. Dührsen, A.M. Risitano, J. Schubert, and L. Luzzatto Effect on the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Blood. 110 2007 4123 4128 (Pubitemid 350248472)
16. Hillmen P. The role of complement inhibition in PNH. Hematology American Society Hematology Educational Program. 2008;116-23
17. Socie G, Muus P, Schrezenmeier H, Maciejewsky J, Weitz I, Hill A, et al. Terminal complement inhibitor eculizumab improves complement-mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009. Abstract 4030.
18. K.M. Chow, F.M. Lai, A.Y. Wang, Y.L. Chan, N.L. Tang, and P.K. Li Reversible renal failure in paroxysmal nocturnal hemoglobinuria Am J Kidney Dis. 37 2001 E17
19. M.D. Jose, and K.L. Lynn Acute renal failure in a patient with paroxysmal nocturnal hemoglobinuria Clin Nephrol. 56 2001 172 174 (Pubitemid 32707828)
20. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Chronic renal insufficiency in Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH): Improvement with eculizumab treatment in the long-term follow-up of the AEGIS Study. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 1980.
21. A. Hill, P. Hillmen, S.J. Richards, D. Elebute, J.C. Marsh, and J. Chan Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria Blood. 106 2005 2559 2565 (Pubitemid 41510834)
22. R.A. Brodsky, P. Muus, U. Dührsen, A. Hill, M. Bessler, and S. Coutre Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results Blood (ASH Annual Meeting Abstracts). 108 2006 3770
23. R.A. Brodsky, N.S. Young, E. Antonioli, A.M. Risitano, H. Schrezenmeier, and J. Schubert Multicentric phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Blood. 111 2008 1840 1847 (Pubitemid 351451491)
24. C. Parker Eculizumab for paroxysmal nocturnal haemoglobinuria Lancet. 373 2009 759 767
25. Parker C. Ask the hematologist. How do I diagnose and treat PNH? The Hematologist. 2008;5:4-5.
26. R.A. Brodsky How I treat paroxysmal nocturnal hemoglobinuria Blood. 113 2009 6522 6527
27. A.M. Risitano, R. Notaro, L. Marando, B. Serio, D. Ranaldi, and E. Séneca Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab Blood. 113 2009 4094 4100
28. Hill Al, S.J. Richards, R.P. Rother, and P. Hillmen Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria Haematologica. 92 2007 e31 33
29. Schrezenmeier H, Schubert J, Luzzatto L, Muus P, Socie G, Risitano AM, et al. Effects of eculizumab therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) receiving concurrent immunosuppressive therapy for bone marrow insufficiency. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 3012.